Bone Density Loss: Tenofovir is connected to a lower in bone mineral density, increasing the risk of bone difficulties or fractures.HIV-1 contaminated subjects on dolutegravir monotherapy demonstrated speedy and dose-dependent reduction of antiviral action with declines of HIV-one RNA copies for every ml. The antiviral response was preserved for th